We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Fluorescence Fingerprinting Assay for Identification of Synthetic Cannabinoid Receptor Agonists

By LabMedica International staff writers
Posted on 14 Nov 2019
Print article
Image: The fluorescence fingerprinting device can test saliva for the presence of the synthetic cannabinoid receptor agonist “spice” in about five minutes (Photo courtesy of University of Bath)
Image: The fluorescence fingerprinting device can test saliva for the presence of the synthetic cannabinoid receptor agonist “spice” in about five minutes (Photo courtesy of University of Bath)
A team of British researchers developed a rapid real-time, point-of-care test for the identification of synthetic cannabinoid receptor agonists (SCRAs), a class of illegal drugs known colloquilly as “Spice” or “K2”.

SCRAs are a family of compounds designed to mimic the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD), the psychoactive molecules in cannabis, by binding to CB1 and CB2 cannabinoid receptors and acting as agonists for receptor function. CB1 receptors are most commonly found in the peripheral and central nervous system, while the structurally smaller CB2 receptors are mostly expressed within the immune system. Under normal endogenous conditions, these cannabinoid receptors have been found to modulate a variety of physiological and cognitive processes including fertility, pregnancy, pre- and postnatal development, appetite, pain sensation, inflammation, mood, and memory, causing a number of major side effects, both psychological and physiological. These include, but are not limited to, acute kidney injury, vomiting, cardiovascular complications, agitation, irritability, confusion, hallucinations, delusions, psychosis, and even death. The severity of these side effects are thought to be due to SCRAs having unusually high binding affinities at CB receptors, coupled with acting as full agonists of CB receptors.

SCRAs are highly potent and addictive drugs that are prevalent in the prison system and among homeless populations in the United Kingdom. SCRAs are chemically diverse, with over a hundred compounds used as recreational drugs. The chemical diversity of SCRA structures presents a challenge in developing techniques to detect them. Typically, GC-MS is used for chemical identification; however, this technology is not usually available in most settings where detection is critical, such as in hospital emergency rooms, in jails or prisons, or among homeless communities.

In this light, investigators at the University of Bath (United Kingdom) sought to develop a real time, point-of-care method for identification of SCRAs.

In a recent paper, they reported that fluorescence spectral fingerprinting, which required only about five minutes to perform, could be used to identify the likely presence of SCRAs, as well as provide more specific information on structural class and concentration. Furthermore, the investigators demonstrated that that fluorescence spectral fingerprints, combined with numerical modeling, could detect both parent and burnt material, and that such fingerprinting was also practical for detecting them in saliva.

Senior author Dr. Chris Pudney, senior lecturer in biology and biochemistry at the University of Bath, said, "My partner is a psychiatrist and she was telling me that currently they do not have a way to confirm when they suspect spice use, they just do not know for sure. You can test for it with a urine or blood sample that is sent off to a lab, but that takes a few days and so in most cases it's pointless. I started looking into the chemistry and it is actually similar to something we have developed for detection of biological molecules. We decided on saliva because it seemed tractable and less invasive than some other options. We have proved the concept with a test that is simple and very accurate. The hardware is compact and portable and the results are easy to understand. We are working on software now, so that the user has a simple “one click” way to use it."

The fluorescence fingerprinting method was described in the September 5, 2019, issue of the journal Analytical Chemistry.

Related Links:
University of Bath

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.